MoonLake Immunotherapeutics (MLTX) Insider Trading Disclosures
MoonLake Immunotherapeutics (MLTX) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: MLTX
CIK: 1821586
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: E9
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Baker Tilly US, LLP
Auditor SinceSince 12/31/2022 12:00:00 AM
Lead Engagement PartnerAnthony Leung
Audit LocationSanta Clara, California, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 8-K | 2026-09-30 | 2026-09-30 | CURRENT REPORT | 0001213900-26-105240 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001172661-26-003691 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-08-14 | — | SCHEDULE 13G Filing | 0001897612-26-000611 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001172661-26-003483 | View SEC Doc Filr Page |
| S-8 | 2026-08-10 | — | REGISTRATION STATEMENT | 0001213900-26-087304 | View SEC Doc Filr Page |
| S-3ASR | 2026-08-10 | — | REGISTRATION STATEMENT | 0001213900-26-087295 | View SEC Doc Filr Page |
| 10-Q | 2026-08-10 | 2026-06-30 | 10-Q | 0001821586-26-000010 | View SEC Doc Filr Page |
| 8-K | 2026-08-10 | 2026-08-10 | CURRENT REPORT | 0001213900-26-086939 | View SEC Doc Filr Page |
| 4 | 2026-07-29 | 2026-07-27 | 4 Filing | 0001213900-26-082804 | View SEC Doc Filr Page |
| 4 | 2026-07-23 | 2026-07-21 | 4 Filing | 0001213900-26-080869 | View SEC Doc Filr Page |
| 4 | 2026-07-21 | 2026-07-20 | 4 Filing | 0001213900-26-080133 | View SEC Doc Filr Page |
| 4 | 2026-07-20 | 2026-07-15 | 4 Filing | 0001213900-26-079376 | View SEC Doc Filr Page |
| 144 | 2026-07-15 | — | 144 Filing | 0001969223-26-000787 | View SEC Doc Filr Page |
| 8-K | 2026-07-15 | 2026-07-14 | CURRENT REPORT | 0001213900-26-078031 | View SEC Doc Filr Page |
| 4 | 2026-07-13 | 2026-07-09 | 4 Filing | 0001213900-26-077564 | View SEC Doc Filr Page |
| 4 | 2026-07-02 | 2026-07-01 | 4 Filing | 0001213900-26-074964 | View SEC Doc Filr Page |
| 144 | 2026-06-30 | — | 144 Filing | 0001969223-26-000744 | View SEC Doc Filr Page |
| SCHEDULE 13D/A | 2026-06-29 | — | SCHEDULE 13D/A Filing | 0000921895-26-001697 | View SEC Doc Filr Page |
| 8-K | 2026-06-25 | 2026-06-23 | CURRENT REPORT | 0001213900-26-071721 | View SEC Doc Filr Page |
| 424B5 | 2026-06-24 | — | PROSPECTUS SUPPLEMENT | 0001213900-26-071586 | View SEC Doc Filr Page |
| 4 | 2026-06-23 | 2026-06-22 | 4 Filing | 0001213900-26-071075 | View SEC Doc Filr Page |
| 424B5 | 2026-06-22 | — | PRELIMINARY PROSPECTUS SUPPLEMENT | 0001213900-26-070709 | View SEC Doc Filr Page |
| 4 | 2026-06-22 | 2026-06-17 | OWNERSHIP DOCUMENT | 0000921895-26-001639 | View SEC Doc Filr Page |
| 8-K | 2026-06-22 | 2026-06-21 | CURRENT REPORT | 0001213900-26-070362 | View SEC Doc Filr Page |
| 4 | 2026-06-18 | 2026-06-17 | 4 Filing | 0001213900-26-070259 | View SEC Doc Filr Page |